|Mr. Jeffrey Alan Wolf J.D.||Founder, Chairman, Chief Exec. Officer, Pres and Treasurer||607.08k||N/A||54|
|Ms. Ann A. Rosar M.B.A.||VP of Fin. & Corp. Sec.||232.39k||N/A||65|
|Dr. Jeff T. Hutchins Ph.D.||Chief Scientific Officer||N/A||N/A||58|
|Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.||Chief Medical Advisor and Member of Scientific & Clinical Advisory Board||N/A||N/A||N/A|
|Colonel George E. Peoples Jr.,M.D., FACS||Chief Medical Officer||N/A||N/A||N/A|
Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.
Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.